Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention

Trials

Volumn 10, Issue , 2009, Pages

  Ethgen, Morgane ^a,b,c   Boutron, Isabelle ^a,b,c   Steg, Philippe Gabriel ^a   Roy, Carine ^a,b,c   Ravaud, Philippe ^a,b,c  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; ARTICLE; BARE METAL STENT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DEATH; DRUG ELUTING STENT; HEART DEATH; HEART INFARCTION; HUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CARDIOVASCULAR DISEASE; INSTRUMENTATION; INTERPERSONAL COMMUNICATION; METHODOLOGY; MORTALITY; PUBLICATION; REVIEW; RISK ASSESSMENT; SAFETY; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; CONSUMER PRODUCT SAFETY; DISCLOSURE; HUMANS; PERIODICALS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 66749112344     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-10-29     Document Type: Article

References (32)

1. Serruys PW Kutryk MJ Ong AT Coronary-artery stents N Engl J Med 2006, 354:483-495 10.1056/NEJMra051091 16452560
2. Erbel R Di Mario C Bartunek J Bonnier J de Bruyne B Eberli FR Erne P Haude M Heublein B Horrigan M Ilsley C Böse D Koolen J Lüscher TF Weissman N Waksman R PROGRESS-AMS (Clinical Performance and Angiographic Results of Coronary Stenting with Absorbable Metal Stents) Investigators Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: A prospective, non-randomised multicentre trial Lancet 2007, 369:1869-1875 10.1016/ S0140-6736(07)60853-8 17544767
3. Maisel WH Unanswered questions - drug-eluting stents and the risk of late thrombosis N Engl J Med 2007, 356:981-984 10.1056/NEJMp068305 17296826
4. Nebeker JR Virmani R Bennett CL Hoffman JM Samore MH Alvarez J Davidson CJ McKoy JM Raisch DW Whisenant BK Yarnold PR Belknap SM West DP Gage JE Morse RE Gligoric G Davidson L Feldman MD Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project J Am Coll Cardiol 2006, 47:175-181 10.1016/j.jacc.2005.07.071 16386683
5. Bavry AA Kumbhani DJ Helton TJ Borek PP Mood GR Bhatt DL Late thrombosis of drug-eluting stents: A meta-analysis of randomized clinical trials Am J Med 2006, 119(12):1056-61 10.1016/j.amjmed.2006.01.023 17145250
6. Bavry AA Chiu JH Jefferson BK Karha J Bhatt DL Ellis SG Whitlow PL Development of coronary aneurysm after drug-eluting stent implantation Ann Intern Med 2007, 146:230-232 17283357
7. Farb A Boam AB Stent thrombosis redux - the FDA perspective N Engl J Med 2007, 356:984-987 10.1056/NEJMp068304 17296827
8. Pfisterer M Brunner-La Rocca HP Buser PT Rickenbacher P Hunziker P Mueller C Jeger R Bader F Osswald S Kaiser C BASKET-LATE Investigators Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 2006, 48:2584-2591 10.1016/ j.jacc.2006.10.026 17174201
9. Camenzind E Steg PG Wijns W Stent thrombosis late after implantation of first-generation drug-eluting stents: A cause for concern Circulation 2007, 115:1440-1455 discussion 1455. 10.1161/CIRCULATIONAHA.106.666800 17344324
10. Serruys PW Daemen J Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: A nuisance in both bare metal and drug-eluting stents Circulation 2007, 115:1433-1439 discussion 1439. 10.1161/CIRCULATIONAHA.106.666826 17344323
11. Lagerqvist B James SK Stenestrand U Lindback J Nilsson T Wallentin L Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden N Engl J Med 2007, 356:1009-1019 10.1056/NEJMoa067722 17296822
12. Kastrati A Mehilli J Pache J Kaiser C Valgimigli M Kelbaek H Menichelli M Sabaté M Suttorp MJ Baumgart D Seyfarth M Pfisterer ME Schömig A Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 2007, 356:1030-1039 10.1056/ NEJMoa067484 17296823
13. Mauri L Hsieh WH Massaro JM Ho KK D'Agostino R Cutlip DE Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 2007, 356:1020-1029 10.1056/NEJMoa067731 17296821
14. Stone GW Moses JW Ellis SG et al Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 2007, 356:998-1008 10.1056/NEJMoa067193 17296824
15. Spaulding C Daemen J Boersma E Cutlip DE Serruys PW A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 2007, 356:989-997 10.1056/NEJMoa066633 17296825
16. Tung R Kaul S Diamond GA Shah PK Narrative review: Drug-eluting stents for the management of restenosis: A critical appraisal of the evidence Ann Intern Med 2006, 144:913-919 16785479
17. McFadden EP et al Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy) Lancet 2004, 364(9444):1519-21 10.1016/S0140-6736(04)17275-9 15500897
18. Ioannidis JP Evans SJ Gotzsche PC O'Neill RT Altman DG Schulz K Moher D CONSORT Group Better reporting of harms in randomized trials: An extension of the CONSORT statement Ann Intern Med 2004, 141:781-788 15545678
19. Ioannidis JP Lau J Improving safety reporting from randomised trials Drug Saf 2002, 25:77-84 10.2165/00002018-200225020-00002 11888350
20. Papanikolaou PN Churchill R Wahlbeck K Ioannidis JP Safety reporting in randomized trials of mental health interventions Am J Psychiatry 2004, 161:1692-1697 10.1176/appi.ajp.161.9.1692 15337661
21. Ethgen M Boutron I Baron G Giraudeau B Sibilia J Ravaud P Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease Ann Intern Med 2005, 143:20-25 15998751
22. Ethgen M Boutron I Steg Ph-G Roy C Ravaud P Quality of Reporting Internal and External Validity Data from Randomized Controlled Trials Evaluating Stents for Percutaneous Coronary Intervention BMC Medical Research. BMC Med Res Methodol 2009, 9:24 10.1186/1471-2288-9-24
23. Boutron I Moher D Altman DG Schulz KF Ravaud P CONSORT Group Methods and processes of the CONSORT Group: Example of an extension for trials assessing nonpharmacologic treatments Ann Intern Med 2008, 148(4):W60-6 18283201
24. Naslund U Grip L Fischer-Hansen J Gundersen T Lehto S Wallentin L The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: Results with and without the end-point committee's final decision on end-points Eur Heart J 1999, 20:771-777 10.1053/euhj.1998.1351 10329069
25. Research USFaDACfBEa Guidance for Clinical Trial Sponsors On the establishment and Operation of Clinical Trial Data Monitoring Committees http://www.fda.gov/CBER/gdlns/clindatmon.pdf
26. Agency EM Committee for Medicinal Products for Human Use http://www.emea.europa.eu/pdfs/human/ewp/587203en.pdf
27. Ives DG Fitzpatrick AL Bild DE Psaty BM Kuller LH Crowley PM Cruise RG Theroux S Surveillance and ascertainment of cardiovascular events Ann Epidemiol 1995, 5:278-285 10.1016/1047-2797(94)00093-9 8520709
28. Mahaffey KW Roe MT Dyke CK Newby LK Kleiman NS Connolly P Berdan LG Sparapani R Lee KL Armstrong PW Topol EJ Califf RM Harrington RA Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial Am Heart J 2002, 143:242-248 10.1067/mhj.2002.120145 11835026
29. Mahaffey KW Harrington RA Akkerhuis M Kleiman NS Berdan LG Crenshaw BS Tardiff BE Granger CB DeJong I Bhapkar M Widimsky P Corbalon R Lee KL Deckers JW Simoons ML Topol EJ Califf RM For the PURSUIT Investigators Systematic adjudication of myocardial infarction end-points in an international clinical trial Curr Control Trials Cardiovasc Med 2001, 2:180-186 57749 11806793 10.1186/CVM-2-4-180
30. Mahaffey KW Harrington RA Akkerhuis M Kleiman NS Berdan LG Crenshaw BS Tardiff BE Granger CB DeJong I Bhapkar M Widimsky P Corbalon R Lee KL Deckers JW Simoons ML Topol EJ Califf RM For the PURSUIT Investigators Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: Review of the PURSUIT study Curr Control Trials Cardiovasc Med 2001, 2:187-194 57750 11806794 10.1186/CVM-2-4-187
31. Cairns JA Hallstrom A Held P Should all trials have a data safety and monitoring committee? Am Heart J 2001, 141:156-163 10.1067/ mhj.2001.112501 11136502
32. Slutsky AS Lavery JV Data safety and monitoring boards N Engl J Med 2004, 350:1143-1147 10.1056/NEJMsb033476 15014189